Trial Profile

A platform study evaluating the efficacy and safety of investigational therapies in participants with chronic hepatitis B infection (PREVAIL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elebsiran (Primary) ; Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Tobevibart (Primary)
Indications Hepatitis B
Focus Therapeutic Use
Acronyms PREVAIL
Sponsors Vir Biotechnology

01 Aug 2024 According to a Vir Biotechnology media release, Initial data from the Phase 2 PREVAIL platform study and its THRIVE/STRIVE sub-protocols is expected in the first half of 2025.
27 Mar 2024 Status changed from active, no longer recruiting to discontinued before starting the recruitment in New Zealand due to delay in start-up and lower enrollment potential.
22 Feb 2024 According to a Vir Biotechnology media release, Initial data from this platform trial is expected in the first half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com